PL2667849T3 - Kompozycja musująca w postaci stałej do zastosowania dopochwowego w leczeniu zakażeń pochwy - Google Patents

Kompozycja musująca w postaci stałej do zastosowania dopochwowego w leczeniu zakażeń pochwy

Info

Publication number
PL2667849T3
PL2667849T3 PL12706669T PL12706669T PL2667849T3 PL 2667849 T3 PL2667849 T3 PL 2667849T3 PL 12706669 T PL12706669 T PL 12706669T PL 12706669 T PL12706669 T PL 12706669T PL 2667849 T3 PL2667849 T3 PL 2667849T3
Authority
PL
Poland
Prior art keywords
vaginal
treatment
solid form
applications
effervescent composition
Prior art date
Application number
PL12706669T
Other languages
English (en)
Inventor
Giovanni Mogna
Gian Paolo Strozzi
Luca Mogna
Original Assignee
Probiotical S.P.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Probiotical S.P.A. filed Critical Probiotical S.P.A.
Publication of PL2667849T3 publication Critical patent/PL2667849T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0007—Effervescent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/742—Spore-forming bacteria, e.g. Bacillus coagulans, Bacillus subtilis, clostridium or Lactobacillus sporogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biotechnology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL12706669T 2011-01-28 2012-01-24 Kompozycja musująca w postaci stałej do zastosowania dopochwowego w leczeniu zakażeń pochwy PL2667849T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
ITMI2011A000107A IT1403661B1 (it) 2011-01-28 2011-01-28 Composizione effervescente in forma solida per uso in applicazioni vaginali per il trattamento di infezioni vaginali.
IT000316A ITMI20110316A1 (it) 2011-01-28 2011-03-01 Composizione effervescente in forma solida per uso in applicazioni vaginali per il trattamento di infezioni vaginali.
EP12706669.4A EP2667849B1 (en) 2011-01-28 2012-01-24 Effervescent composition in solid form for use in vaginal applications for the treatment of vaginal infections
PCT/IB2012/000095 WO2012101500A1 (en) 2011-01-28 2012-01-24 Effervescent composition in solid form for use in vaginal applications for the treatment of vaginal infections

Publications (1)

Publication Number Publication Date
PL2667849T3 true PL2667849T3 (pl) 2020-06-15

Family

ID=43975441

Family Applications (1)

Application Number Title Priority Date Filing Date
PL12706669T PL2667849T3 (pl) 2011-01-28 2012-01-24 Kompozycja musująca w postaci stałej do zastosowania dopochwowego w leczeniu zakażeń pochwy

Country Status (22)

Country Link
US (2) US9492377B2 (pl)
EP (1) EP2667849B1 (pl)
JP (1) JP5992446B2 (pl)
KR (1) KR101913797B1 (pl)
CN (1) CN104519866A (pl)
AU (1) AU2012210296B2 (pl)
BR (1) BR112013018953B1 (pl)
CL (1) CL2013002148A1 (pl)
CO (1) CO6771428A2 (pl)
DK (1) DK2667849T3 (pl)
EC (1) ECSP13012844A (pl)
ES (1) ES2751416T3 (pl)
IT (2) IT1403661B1 (pl)
MA (1) MA34926B1 (pl)
MX (1) MX347165B (pl)
PE (2) PE20180413A1 (pl)
PL (1) PL2667849T3 (pl)
PT (1) PT2667849T (pl)
RU (1) RU2587717C2 (pl)
TN (1) TN2013000310A1 (pl)
UA (1) UA114888C2 (pl)
WO (1) WO2012101500A1 (pl)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1403661B1 (it) 2011-01-28 2013-10-31 Probiotical Spa Composizione effervescente in forma solida per uso in applicazioni vaginali per il trattamento di infezioni vaginali.
ITMI20110791A1 (it) 2011-05-09 2012-11-10 Probiotical Spa Ceppi di batteri in grado di metabolizzare gli ossalati.
ITMI20110793A1 (it) 2011-05-09 2012-11-10 Probiotical Spa Ceppi di batteri probiotici e composizione sinbiotica contenente gli stessi destinata alla alimentazione dei neonati.
ITMI20110792A1 (it) 2011-05-09 2012-11-10 Probiotical Spa Ceppi di batteri appartenenti al genere bifidobacterium per uso nel trattamento della ipercolesterolemia.
ITRM20110477A1 (it) 2011-09-09 2013-03-10 Giovanni Mogna Composizione comprendente n-acetilcisteina e/o lisozima microincapsulato gastroprotetto in associazione con batteri probiotici in grado di ripristinare l'effetto barriera proprio dello stomaco che viene perso durante il trattamento farmacologico dell
ITMI20111718A1 (it) 2011-09-23 2013-03-24 Probiotical Spa Un materiale impermeabile alla umidita e allo ossigeno per confezionare prodotti dietetici, cosmetici e specialita medicinali.
ITMI20130793A1 (it) * 2013-05-14 2014-11-15 Probiotical Spa Composizione comprendente batteri lattici per uso nel trattamento preventivo e/o curativo delle cistiti ricorrenti.
ITMI20130794A1 (it) * 2013-05-14 2014-11-15 Probiotical Spa Composizione comprendente batteri lattici per uso nel trattamento preventivo e/o curativo delle vaginosi batteriche.
ITMI20130795A1 (it) * 2013-05-14 2014-11-15 Probiotical Spa Composizione comprendente batteri lattici e/o bifidobatteri per uso nel trattamento preventivo e/o curativo delle infezioni batteriche e/o delle infiammazioni del tratto urinario e/o della prostata che sono la causa di prostatiti e ipertrofia prostat
TWI643626B (zh) * 2013-08-12 2018-12-11 西班牙商巨妮亞實驗室有限公司 作為益生菌之乳桿菌屬菌株
CA2985729C (en) 2015-05-11 2023-05-09 Mybiotics Pharma Ltd Systems and methods for growing a biofilm of probiotic bacteria on solid particles for colonization of bacteria in the gut
KR101980252B1 (ko) 2015-05-26 2019-05-21 (주)투라인스 질증 치료용 조성물
KR102713511B1 (ko) * 2015-06-29 2024-10-04 훼링 비.브이. 세균성 질증의 치료를 위한 락토바실러스 람노서스 박테리아
ITUB20153106A1 (it) * 2015-08-13 2017-02-13 Probiotical Spa Composizione di batteri lattici per uso nel trattamento delle infezioni causate da Propionibacterium acnes e in particolare per l'acne
US11166968B2 (en) 2015-09-29 2021-11-09 Kimberly-Clark Worldwide, Inc. Synergistic composition for maintenance of healthy balance of microflora
CN105534948B (zh) * 2015-12-17 2019-05-03 内蒙古双奇药业股份有限公司 一种可常温保存的阴道用活菌制剂及其制备方法
ITUB20159330A1 (it) * 2015-12-22 2017-06-22 Roelmi Hpc S R L Composizioni probiotiche e loro uso
BE1023643B1 (nl) * 2016-03-21 2017-06-01 Yun NV Vaginale preparaten voor het onderhouden en / of herstellen van een gezonde vrouwelijke microbiota
ITUA20162013A1 (it) * 2016-03-24 2017-09-24 Probiotical Spa Composizione a base di batteri lattici per il trattamento contemporaneo di infezioni vaginali di origine micotica e batterica.
WO2017163216A1 (en) * 2016-03-24 2017-09-28 Probiotical S.P.A. Lactic acid bacterial composition for the treatment of bacterial vaginal infections by gardnerella vaginalis and, if present, of concurrent fungal infections
BR112018071307A2 (pt) * 2016-04-18 2019-02-26 Celldex Therapeutics, Inc. anticorpos agonistas que ligam cd40 humana e usos dos mesmos
KR102380134B1 (ko) 2016-05-25 2022-03-29 마이바이오틱스 파마 엘티디. 미생물총 치료를 위한 조성물 및 방법
CA3040422A1 (en) * 2016-10-13 2018-04-19 Catalent U.K. Swindon Zydis Limited Lyophilized pharmaceutical compositions for vaginal delivery
KR102769558B1 (ko) 2017-02-28 2025-02-19 킴벌리-클라크 월드와이드, 인크. 미생물총의 건강한 균형을 유지하기 위한 상승적 조성물
CN106798755B (zh) * 2017-03-10 2020-09-15 山东神农医院管理有限公司 一种具有调理乳腺增生功能的益生菌组合物及其应用
CN106692204B (zh) * 2017-03-10 2020-05-22 泰安大凡神农生物有限公司 一种缓解或改善盆腔炎症的益生菌组合物及其制备方法
KR102014810B1 (ko) * 2017-09-04 2019-08-27 라임바이오파마 주식회사 질염 예방 및 치료용 조성물
TWI703991B (zh) * 2017-09-29 2020-09-11 榮華 曹 供給二氧化碳氣體的衛生用品
CN109846846A (zh) * 2018-12-20 2019-06-07 赛奈金生物科技(上海)有限公司 一种含益生菌的泡腾缓释剂及其制备方法和应用
IT201800020425A1 (it) 2018-12-20 2020-06-20 Univ Degli Studi Di Modena E Reggio Emilia Lattobacilli con attività antimicrobica
CN109740292A (zh) * 2019-01-30 2019-05-10 中国测绘科学研究院 一种基于多智能体的城市人口空间分布估算方法及装置
US11045507B2 (en) 2019-02-21 2021-06-29 Ewelina Sosnowska-Turek Bifidobacterium animalis AMT30 strain and the composition containing the strain of Bifidobacterium animalis AMT30
KR102063757B1 (ko) * 2019-05-03 2020-01-08 주식회사 메디오젠 가드네렐라 바기날리스 및 칸디다 알비칸스에 항균 효과를 갖는 질염 치료 또는 개선용 유산균
CN110547915A (zh) * 2019-08-29 2019-12-10 云南白药清逸堂实业有限公司 应用益生菌的卫生棉制品及其制备方法
CN111647525B (zh) * 2020-05-18 2022-08-05 深圳华大基因农业控股有限公司 复合益生菌、菌剂及其在制备防治白色念珠菌性阴道炎菌剂中的应用
JP7594980B2 (ja) * 2021-06-22 2024-12-05 株式会社ヤクルト本社 単純ヘルペスウイルスの再活性化抑制用組成物
KR102444746B1 (ko) * 2021-09-16 2022-09-19 일동바이오사이언스(주) 락토바실러스 카제이 idcc 3451을 포함하는 질염에 유용한 조성물
WO2023080764A1 (ko) * 2021-11-08 2023-05-11 주식회사 씨티씨바이오 질염 또는 요로감염증 유발 미생물에 항균활성을 지닌 유산균 및 그의 용도
CN114350576B (zh) * 2022-03-17 2022-06-07 烟台欣和企业食品有限公司 提高料酒抗风险能力的乳杆菌及其应用
EP4522124A4 (en) * 2022-05-12 2026-04-15 One Bio Inc METHODS OF TREATING UROGENITAL HEALTH PROBLEMS
KR102946295B1 (ko) * 2023-06-19 2026-04-02 주식회사 쎌바이오텍 락토바실러스 람노서스 CBT LR6-feminine (Lactobacillus rhamnosus CBT LR6-feminine)를 포함하는 조성물
KR20260006643A (ko) * 2023-06-20 2026-01-13 토요 슈가 리파이닝 컴퍼니 리미티드 세균의 증식 억제제, 그것을 포함하는 화장품, 의약 부외품 및 의약 조성물, 그리고 세균의 증식 억제 방법

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3819838A (en) 1970-08-04 1974-06-25 Bush Boake Allen Ltd Encapsulated flavoring composition
JPS53121949A (en) 1977-03-31 1978-10-24 Yakult Honsha Kk Production of drink and food containing bifidobacterium cells
DE2757370A1 (de) 1977-12-22 1979-07-05 Bayer Ag Gasdichte kunststoff-aluminium-verbundfolien
CH637297A5 (fr) 1978-12-05 1983-07-29 Nestle Sa Microbille comprenant un microorganisme et son procede de fabrication.
JPS58152809A (ja) * 1982-03-05 1983-09-10 Eisai Co Ltd 安定な発泡性「膣」坐剤
US4670272A (en) 1985-11-08 1987-06-02 Frito-Lay, Inc. Thermostable creme
US5343672A (en) 1992-12-01 1994-09-06 Scherer Ltd R P Method for manufacturing freeze dried dosages in a multilaminate blister pack
AU1758197A (en) * 1996-02-14 1997-09-02 Procter & Gamble Company, The Urogenital and intestinal compositions
EP0845350A1 (de) 1996-11-29 1998-06-03 Alusuisse Technology & Management AG Kalt-verformbare Verbundfolie
EP1067945B1 (en) 1998-04-01 2006-01-04 Ganeden Biotech, Inc. Methods for reducing cholesterol using bacillus coagulans spores, systems and compositions
PT956858E (pt) * 1998-04-30 2002-04-29 Renata Maria Anna Caval Vesely Composicoes farmaceuticas contendo lactobacilos para o tratamento de infeccoes vaginais
RU2150268C1 (ru) 1998-12-25 2000-06-10 Быков Валерий Алексеевич Суппозиторий с лактобактериями для лечения дисбактериозов влагалища
IT1309427B1 (it) 1999-05-28 2002-01-23 Mendes S U R L Composizione dietetica o farmaceutica utile per la prevenzione o iltrattamento dell'iperossaluria e suo uso
CN1234373C (zh) 2000-09-28 2006-01-04 信谊药厂 含嗜酸乳杆菌的药物制剂及制备方法
WO2004101770A1 (en) 2003-03-13 2004-11-25 Universite De Moncton (Bureau De Soutien A L'innovation) Antioxidant producing bacterium and uses thereof
US20040185032A1 (en) 2003-03-18 2004-09-23 David Burrell Compositions and methods for treating colic
EP1631243B1 (en) 2003-04-09 2013-05-15 Dolhay Klinika Egészségügyi KFT. Sexual hygienic composition
JP4740866B2 (ja) 2003-10-24 2011-08-03 ナムローゼ フェンノートシャップ ニュートリシア 乳児向けシンバイオティック組成物
ATE289514T1 (de) 2003-11-03 2005-03-15 Peter-Hansen Volkmann Vaginalpflegezusammensetzung
GB0330009D0 (en) * 2003-12-24 2004-01-28 Ferrosan As Probiotic tablet formulations
GB0405406D0 (en) 2004-03-10 2004-04-21 Edko Pazarlama Tanitim Ltd Sti Anti-vaginitis compositions
EP1600060A1 (en) 2004-05-25 2005-11-30 Cognis IP Management GmbH Oral and/or topical compositions comprising prebiotics and fatty acid
EP1600061B1 (en) 2004-05-25 2010-05-12 Cognis IP Management GmbH Oral and/or topical compositions
BRPI0418986A (pt) 2004-08-05 2007-12-11 Anidral Srl cepas bacterianas bifidobacterium produtoras de ácido fólico, formulações e seus usos
US20060039973A1 (en) * 2004-08-19 2006-02-23 Mary Aldritt Effervescent composition including water soluble dietary fiber
WO2006047680A2 (en) 2004-10-27 2006-05-04 North Carolina State University Lactobacillus acidophilus nucleic acids and uses thereof
KR100661032B1 (ko) 2005-04-19 2006-12-22 주식회사한국야쿠르트 간 기능 개선, 혈중 알코올 감소 및 항산화에 유효한조성물
WO2007100765A2 (en) 2006-02-28 2007-09-07 Childrens Memorial Hospital Lysozyme-modified probiotic components and uses thereof
RU2318523C2 (ru) 2006-03-13 2008-03-10 Лев Давидович Раснецов Средство антимикробного действия
EP2269465A1 (en) 2006-05-03 2011-01-05 Probiotical S.p.a. Compositions comprising Bifidobacterium adolescentis
ITMI20061841A1 (it) 2006-09-27 2008-03-28 Mofin S R L Colture liquide microbiche ad elevata stabilita' ed attivita' fermentativa
ITMI20062286A1 (it) * 2006-11-28 2008-05-29 Anidral Srl Una composizione per la somministrazione di principi biologicamente attivi in ambito ginecologico e rettale nonche' i suoi usi
US20080175899A1 (en) 2007-01-19 2008-07-24 Ross Mairi R Formulation for promoting sinus health in nasal cavities
US20080187628A1 (en) 2007-02-02 2008-08-07 Champion Melinda L Water-Soluble, Quick-Dissolve Flavor Tablets
PL210465B1 (pl) 2007-06-04 2012-01-31 Inst Biotechnologii Surowic I Szczepionek Biomed Społka Akcyjna Zastosowanie kompozycji szczepów z rodzaju Lactobacillus
WO2008153377A1 (en) 2007-06-15 2008-12-18 N.V. Nutricia Nutrition with non-viable bifidobacterium and non-digestible oligosaccharide
DE102008023952A1 (de) 2008-05-16 2009-12-03 Alcan Technology & Management Ag Verpackungs-Deckfolie, Behältnis, Verpackung und Verpackungs-Produkt-Einheit
EP2318511B1 (en) 2008-08-28 2017-08-02 Chr. Hansen A/S Bacterial composition
KR101618391B1 (ko) 2008-09-30 2016-05-04 가부시키가이샤 메이지 높은 옥살산 분해능을 갖는 유산균
ES2778836T3 (es) 2009-03-05 2020-08-12 Probiotical Spa Cepas de bacterias que tienen una alta actividad antiinflamatoria
IT1400821B1 (it) 2009-03-09 2013-07-02 Probiotical Spa Sospensione oleosa contenente batteri probiotici per uso pediatrico
FI20095550A0 (fi) 2009-05-19 2009-05-19 Bayer Schering Pharma Oy Vaginaalinen antojärjestelmä
IT1397566B1 (it) 2009-05-27 2013-01-16 Probiotical Spa Lactobacillus pentosus produttore di batteriocine, composizioni alimentari e farmaceutiche contenenti lo stesso e relativo uso
CN102595935A (zh) 2009-07-27 2012-07-18 雀巢产品技术援助有限公司 包含纤维和益生菌的营养组合物
WO2011012932A1 (en) 2009-07-30 2011-02-03 Compagnie Gervais Danone Use of coated sterol or stanol particles for the preparation of food compositions having a low fat content and being essentially emulsifier-free
IT1398553B1 (it) 2010-03-08 2013-03-01 Probiotical Spa Composizione comprendente batteri probiotici per il trattamento di patologie associate con le alterazioni del sistema immunitario.
RU2544054C2 (ru) 2010-06-28 2015-03-10 Пробиотикал С.п.А. Применение молочнокислых бактерий, ингибирующих газообразующие колиформные бактерии, выделенные от новорожденных, страдающих коликами
IT1403661B1 (it) 2011-01-28 2013-10-31 Probiotical Spa Composizione effervescente in forma solida per uso in applicazioni vaginali per il trattamento di infezioni vaginali.
ITMI20110791A1 (it) 2011-05-09 2012-11-10 Probiotical Spa Ceppi di batteri in grado di metabolizzare gli ossalati.
ITRM20110475A1 (it) 2011-09-09 2013-03-10 Probiotical Spa Ceppi di batteri lattici e/o bifido batteri, opzionalmente addizionati di n-acetilcisteina e/o lisozima microincapsulato gastroprotetto, aventi attivita' di inibizione/riduzione della crescita di differenti biotipi di e.coli, incluso e.coli o157:h7 e
ITRM20110477A1 (it) 2011-09-09 2013-03-10 Giovanni Mogna Composizione comprendente n-acetilcisteina e/o lisozima microincapsulato gastroprotetto in associazione con batteri probiotici in grado di ripristinare l'effetto barriera proprio dello stomaco che viene perso durante il trattamento farmacologico dell

Also Published As

Publication number Publication date
WO2012101500A1 (en) 2012-08-02
IT1403661B1 (it) 2013-10-31
JP5992446B2 (ja) 2016-09-14
ITMI20110316A1 (it) 2012-07-29
PE20180413A1 (es) 2018-03-01
MA34926B1 (fr) 2014-02-01
KR101913797B1 (ko) 2018-11-01
DK2667849T3 (da) 2019-10-28
US20170014335A1 (en) 2017-01-19
BR112013018953A2 (pt) 2017-07-11
TN2013000310A1 (en) 2015-01-20
US9492377B2 (en) 2016-11-15
RU2587717C2 (ru) 2016-06-20
CL2013002148A1 (es) 2014-05-16
UA114888C2 (uk) 2017-08-28
CO6771428A2 (es) 2013-10-15
EP2667849B1 (en) 2019-07-24
KR20140029392A (ko) 2014-03-10
MX347165B (es) 2017-04-18
JP2014503581A (ja) 2014-02-13
AU2012210296B2 (en) 2017-01-05
ECSP13012844A (es) 2015-02-28
ES2751416T3 (es) 2020-03-31
NZ614002A (en) 2015-11-27
BR112013018953B1 (pt) 2020-12-29
MX2013008547A (es) 2013-12-02
EP2667849A1 (en) 2013-12-04
RU2013137656A (ru) 2015-03-10
PT2667849T (pt) 2019-10-29
US20140065115A1 (en) 2014-03-06
ITMI20110107A1 (it) 2012-07-29
PE20140259A1 (es) 2014-03-08
AU2012210296A1 (en) 2013-08-22
CN104519866A (zh) 2015-04-15

Similar Documents

Publication Publication Date Title
PT2667849T (pt) Composição efervescente em forma sólida para utilização em aplicações vaginais para o tratamento de infeções vaginais
PL2627334T3 (pl) Kompozycje do stosowania w leczeniu zakażeń wirusowych
PT2736488E (pt) Composições farmacêuticas contendo rifaximina, processos para a sua preparação e sua utilização no tratamento de infeções vaginais
IL235923A0 (en) Aminotriazolopyridine for use in the treatment of inflammation, and pharmaceutical preparations thereof
GB201512357D0 (en) Cannabinoids for use in the treatment of neuropathic pain
PT2575971E (pt) Extratos combinados de plantas para utilização no tratamento de infeções microbianas
GB2515439B (en) Vesicular formulations for use in the treatment of reduced mobility
PL2903608T3 (pl) Kompozycja farmaceutyczna obejmująca kwas propionowy do stosowania w leczeniu infekcji wirusowych
PL2845598T3 (pl) Preparat do stosowania w profilaktyce i leczeniu nietypowej osteoporozy
GB2515440B (en) Vesicular Formulations for use in the treatment of Rosacea
ZA201307058B (en) Use of polyaminoisoprenyl derrivatives in antobiotic or antisertic treatment
PL2676657T3 (pl) Bolus do leczenia hipokalcemii u przeżuwaczy
SG11201405778WA (en) Use of amphoteric surfactants for the prevention and treatment of pathogenic vaginal biofilms in vaginal infections
ZA201308025B (en) The use of secnidazole in treating dental infections
LT2863932T (lt) Kompozicija, skirta naudoti limfedemos gydymui
PL2771016T3 (pl) Prymycyna i jej składniki do zastosowania w leczeniu lub zapobieganiu infekcjom powodowanym przez określone patogeny
IL219444A (en) Procine for use in the treatment of blood cell infections
HRP20150141T1 (xx) Upotreba nifuratela u lijeäśenju infekcija uzrokovanih klostridijima
SI2797914T1 (sl) Nifuratel sulfoksid za uporabo pri zdravljenju bakterijskih infekcij
GB201208770D0 (en) Compounds for use in the treatment of adenovirus infections
HUP1100245A2 (en) Pharmaceutical composition for the treatment of wounds